Zealand Pharma Feed

2024-04-19 22:20:56 Correction to Company announcement – No. 23 / 2024

2024-04-19 17:05:00 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

2024-04-19 17:00:00 Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 2024

2024-03-31 17:00:00 Total number of shares and voting rights in Zealand Pharma at March 31, 2024 -3,67% | 239 MDKK

2024-03-26 22:05:00 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons -2,36% | 689 MDKK

2024-03-26 22:00:00 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants -2,36% | 689 MDKK

2024-03-21 18:00:00 Zealand Pharma major shareholder announcement: Van Herk Investments +1,05% | 877 MDKK

2024-03-20 17:39:42 Zealand Pharma's Annual General Meeting 2024 +3,04% | 907 MDKK

2024-03-19 17:05:00 Zealand Pharma major shareholder announcement: Polar Capital -4,16% | 646 MDKK

2024-03-19 17:00:00 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons -4,16% | 646 MDKK

2024-03-13 22:00:00 New Employee Elected Directors to the Board of Zealand Pharma A/S +0,43% | 1215 MDKK

2024-03-08 17:00:00 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons -6,86% | 551 MDKK

2024-03-05 22:05:00 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons -1,46% | 1022 MDKK

2024-03-05 22:00:00 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants -1,46% | 1022 MDKK

2024-03-01 17:00:00 Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference +1,85% | 317 MDKK

2024-02-27 07:05:00 Zealand Pharma convenes its Annual General Meeting 2024 -4,39% | 2019 MDKK

2024-02-27 07:00:00 Zealand Pharma Announces Financial Results for the Full Year 2023 -4,39% | 2019 MDKK

2024-02-26 08:06:39 Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis +35,67% | 2680 MDKK

2024-02-20 08:00:00 Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results +1,04% | 610 MDKK

2024-01-31 17:00:00 Total number of shares and voting rights in Zealand Pharma at January 31, 2024 -0,38% | 602 MDKK

2024-01-26 18:00:00 Zealand Pharma major shareholder announcement: Van Herk Investments +1,84% | 180 MDKK

2024-01-19 17:30:00 Zealand Pharma major shareholder announcement: J O Hambro Capital Management +2,71% | 110 MDKK

2024-01-17 16:30:00 Zealand Pharma major shareholder announcement: J O Hambro Capital Management +0,09% | 488 MDKK

2024-01-12 11:00:00 Zealand Pharma completes registration of capital increase +2,32% | 642 MDKK

2024-01-10 17:15:00 Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC +1,49% | 1304 MDKK

2024-01-08 21:45:22 Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion +4,51% | 1039 MDKK

2024-01-02 08:00:00 Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th -4,72% | 404 MDKK

2023-12-29 17:00:00 Total number of shares and voting rights in Zealand Pharma at December 29, 2023 -4,72% | 181 MDKK

2023-12-23 10:47:54 U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility +0,59% | 117 MDKK

2023-12-22 10:30:00 Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome +0,43% | 146 MDKK

2023-12-22 08:00:00 Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank +0,43% | 146 MDKK

2023-12-07 22:05:00 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons +1,71% | 229 MDKK

2023-12-07 22:00:00 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants +1,71% | 229 MDKK

2023-12-04 08:30:00 Zealand Pharma to highlight obesity pipeline at R&D Event on December 5 +3,09% | 411 MDKK

2023-12-04 08:00:00 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons +3,09% | 411 MDKK

2023-11-30 17:15:00 Total number of shares and voting rights in Zealand Pharma at November 30, 2023 -1,73% | 233 MDKK

2023-11-30 08:00:00 Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers +2,63% | 373 MDKK

2023-11-16 22:00:00 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants -0,79% | 160 MDKK

2023-11-09 07:00:00 Zealand Pharma Announces Financial Results for the First Nine Months of 2023 +2,83% | 252 MDKK

2023-11-07 10:00:00 Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023 -1,79% | 122 MDKK

2023-11-03 17:00:00 Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results -4,52% | 76,0 MDKK

2023-10-20 22:00:00 Zealand Pharma major shareholder announcement: Polar Capital 0,00% | 70,1 MDKK

2023-10-17 08:00:00 Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek +0,75% | 93,5 MDKK

2023-10-05 11:53:22 Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease +0,06% | 272 MDKK

2023-09-29 17:15:00 Total number of shares and voting rights in Zealand Pharma at September 29, 2023 -0,98% | 73,7 MDKK

2023-09-14 22:30:00 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons -1,45% | 391 MDKK

2023-09-14 22:00:00 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants -1,45% | 391 MDKK

2023-09-08 11:00:00 SAVE THE DATE: Zealand Pharma to host Obesity R&D Event in London on December 5, 2023 +1,04% | 61,4 MDKK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Zealand Pharma

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden